Stock Analysis
By Rajendra 20 Nov, 2022
Listed on BSE
Image Credit-Unsplash
52 week High/low - 3784/2835
CMP - 3,125
Target - 3,680
Producing branded generics, generic medications, active pharmaceutical ingredients (APIs), and nutraceuticals, Alkem Laboratories Ltd sells them in India and other countries.
Image Credit-Unsplash
In terms of domestic sales, Alkem is the fifth-largest pharmaceutical firm in India.
Image Credit-Unsplash
During September 2022 quarter, the Company has filed 3 abbreviated new drug applications (ANDAs) with the US FDA and received 4 approvals.
Image Credit-Unsplash
Company will be focusing on the molecules which have a large prescriber base, particularly antihypertensives and lipid management
Image Credit-Unsplash
company has strong balance sheet and is focusing on improving margins with cost optimization going forward.
Image Credit-Unsplash
New launches in the domestic market and focus on molecules, which have a large prescriber base indicate future growth visibility.
Image Credit-Unsplash
In 6-8 months, it is anticipated that the stock would reach its price goal of Rs. 3680.
Image Credit-Unsplash